DRAGONFLY OPSTAR
Device
Abbott Laboratories
Total Payments
$2.4M
Transactions
5,388
Doctors
1,642
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $351,491 | 1,493 | 681 |
| 2023 | $873,837 | 1,562 | 709 |
| 2022 | $1.2M | 2,332 | 678 |
| 2021 | $4,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 438 | 50.8% |
| Consulting Fee | $517,683 | 262 | 21.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $306,552 | 128 | 12.5% |
| Food and Beverage | $200,587 | 4,197 | 8.2% |
| Travel and Lodging | $97,373 | 307 | 4.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $42,300 | 40 | 1.7% |
| Space rental or facility fees (teaching hospital only) | $25,600 | 8 | 1.0% |
| Debt forgiveness | $6,707 | 3 | 0.3% |
| Grant | $4,000 | 1 | 0.2% |
| Education | $594.31 | 4 | 0.0% |
Payments by Type
Research
$1.2M
438 transactions
General
$1.2M
4,950 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Optical Coherence Tomography Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized Trial in PCI | Abbott Laboratories | $334,169 | 0 |
| Intraoperative Optical Coherence Tomography of the Saphenous Vein Conduit in Patients Undergoing Coronary Artery Bypass Surgery (OCTOCAB) | Abbott Laboratories | $200,000 | 0 |
| Validation of OCT-based FUSION Study | Abbott Laboratories | $170,758 | 0 |
| Imaging-Guided Vessel Sizing in the Tibial Arteries | Abbott Laboratories | $115,000 | 0 |
| Abbott Vascular Medical Device Registry | Abbott Laboratories | $92,757 | 0 |
| Abbott Vascular Medical Device Registry (AV-MDR) | Abbott Laboratories | $87,381 | 0 |
| Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized TriaL in PCI | Abbott Laboratories | $74,520 | 0 |
| Association of Cardiac Allograft Vasculopathy Plaque Characteristics by Optical Coherence Tomography with Coronary Physiology Early after Heart Transplantation | Abbott Laboratories | $59,477 | 0 |
| AVIs Optical Coherence Tomography Dragonfly Optis Imaging Catheter | Abbott Laboratories | $59,476 | 0 |
| Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized Trial in PCI | Abbott Laboratories | $30,435 | 0 |
| Functional Diagnosis of Coronary Stenosis (FUSION) | Abbott Laboratories | $8,090 | 0 |
| Validation of OCT-based FUnctional diagnoSIs of corONary Stenosis (FUSION) | Abbott Laboratories | $6,823 | 0 |
| FUnctional diagnoSIs of corONary Stenosis (FUSION) | Abbott Laboratories | $3,564 | 0 |
Top Doctors Receiving Payments for DRAGONFLY OPSTAR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Roslyn, NY | $1.5M | 467 |
| , MD, PHD | Cardiovascular Disease | Chestnut Hill, MA | $89,782 | 20 |
| , M.D | Cardiovascular Disease | Washington, DC | $49,149 | 72 |
| , M.D | Internal Medicine | Boston, MA | $47,597 | 35 |
| , D.O | Internal Medicine | Lincoln, NE | $32,561 | 24 |
| , MD | Internal Medicine | Boston, MA | $32,162 | 8 |
| , M.D., M.H.A | Cardiovascular Disease | New York, NY | $30,780 | 16 |
| , MD | Internal Medicine | Baltimore, MD | $24,225 | 15 |
| , M.D | Interventional Cardiology | Kyle, TX | $17,028 | 23 |
| , M.D | Internal Medicine | Wyoming, MI | $15,212 | 21 |
| , MD | Cardiovascular Disease | Austin, TX | $14,718 | 22 |
| , MD | Cardiovascular Disease | Atlanta, GA | $14,486 | 2 |
| , M.D | Interventional Cardiology | Washington, DC | $14,250 | 15 |
| , M.D | Cardiovascular Disease | Portland, OR | $14,213 | 3 |
| , MD | Cardiovascular Disease | Providence, RI | $13,624 | 3 |
| , M.D | Cardiovascular Disease | Beverly Hills, CA | $13,304 | 64 |
| , MD | Interventional Cardiology | Eatontown, NJ | $13,092 | 17 |
| , MD | Cardiovascular Disease | Minneapolis, MN | $12,098 | 4 |
| , MD | Cardiovascular Disease | Portland, OR | $10,866 | 15 |
| , M.D | Cardiovascular Disease | Sacramento, CA | $10,498 | 18 |
| , MD | Internal Medicine | Covington, LA | $10,273 | 7 |
| , M.D | Interventional Cardiology | Dallas, TX | $10,240 | 14 |
| , MD | Cardiovascular Disease | Burr Ridge, IL | $9,677 | 9 |
| , M.D | Cardiovascular Disease | Orange, CA | $9,269 | 5 |
| , M.D | Cardiovascular Disease | Mountain View, CA | $8,400 | 7 |
Ad
Manufacturing Companies
- Abbott Laboratories $2.4M
Product Information
- Type Device
- Total Payments $2.4M
- Total Doctors 1,642
- Transactions 5,388
About DRAGONFLY OPSTAR
DRAGONFLY OPSTAR is a device associated with $2.4M in payments to 1,642 healthcare providers, recorded across 5,388 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2021 to 2024. In 2024, $351,491 was paid across 1,493 transactions to 681 doctors.
The most common payment nature for DRAGONFLY OPSTAR is "Unspecified" ($1.2M, 50.8% of total).
DRAGONFLY OPSTAR is associated with 13 research studies, including "Optical Coherence Tomography Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized Trial in PCI" ($334,169).